- World Pharma News Home » Financial » EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline
(a free service delivered by FeedBurner)
EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK) for a consideration of up to US$44 million, comprising an upfront fee and development milestones, plus royalties on future sales. As part of the agreement EUSA will pay approximately 50% of the overall consideration to its development partner for the antibody, Vaccinex Inc. GSK will fund and conduct all future development, production and commercialization of the product.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments